Publications
Search our bibliography using the filters on the right-hand side.
Displaying 1 through 35 of 35 publications.
Skip to main content
Li D, Darden C, Osman N, Sayeed S, Jackson L, Garbinsky D, Chauhan A. Real-world clinical and patient-reported outcomes from the longitudinal telotristat ethyl treatment registry of patients with neuroendocrine tumors. Cancer Manag Res. 2022 Oct 17;14:3009-20. doi: 10.2147/CMAR.S386419
Krege JH, Gilsenan AW, Komacko JL, Kellier-Steele N. Teriparatide and osteosarcoma risk: history, science, elimination of boxed warning, and other label updates. J Bone Miner Res. 2022 Aug 14;6(9):e10665. doi: 10.1002/jbm4.10665
Whalley D, Belongie K, Frangiosa T, Krasa H, Mladsi DM, Twiss J, Wolowacz S. Understanding the patient experience of erythropoietic protoporphyria and x-linked protoporphyria: a qualitative study. Poster presented at the ISPOR 2022 Conference; May 15, 2022. Washington, DC. [abstract] Value Health. 2022 Jun; 25(6 S1).
Layton JB, Forns J, Turner ME, Dempsey C, Bartsch JL, Anthony MS, Danysh HE, Ritchey ME, Demos G. Falls and fractures in patients with Parkinson's Disease–related psychosis treated with Pimavanserin vs atypical antipsychotics: a cohort study. Drugs Real World Outcomes. 2022 Mar;9(1):9-22. doi: 10.1007/s40801-021-00284-1
Forns J, Layton JB, Bartsch J, Turner ME, Dempsey C, Anthony M, Ritchey ME, Demos G. Increased risk of falls and fractures in patients with psychosis and Parkinson disease. PLoS One. 2021 Jan 27. doi: 10.1371/journal.pone.0246121
Forns J, Layton JB, Bartsch J, Turner ME, Dempsey C, Anthony M, Ritchey ME, Demos G. Increased risk of falls and fractures in patients with psychosis and Parkinson disease. Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.
Cawson M, Wolowacz S, Doward L, Sinha A. Health utility estimates for congenital cytomegalovirus disease: conceptual design considerations. Poster presented at the ISPOR 2019 European Conference; November 5, 2019. Copenhagen, Denmark. [abstract] Value Health. 2019 Dec; 22(S3).
Nance R, Vannappagari V, Johannes C, Calingaert B, Saltus C, Boswell S, Rodriguez B, Moore R, Eron J, Geng E, Mathews WC, Saag MS, Kitahata M, Delaney JAC, Crane HM, Centers For AIDS Research Network of Integrated Clinical Systems (CNICS). Viral failure among persons living with HIV initiating dolutegravir-based vs. other recommended regimens in real-world clinical care settings. Poster presented at the IDWeek 2017 Conference; October 2017. San Diego, CA. [abstract] Open Forum Infect Dis. 2017 Oct 4; 4((Suppl 1)):S39. doi: 10.1093/ofid/ofx162.095
Hallas J, Margulis AV, Pottegard A, Kaye JA, Kristiansen N, Bui CL, Atsma WJ, Appenteng K, Franks B, de Vogel S, D'Silva M, Perez-Gutthann S, Arana A. Elevated bladder and prostate cancer rates following initiation of OAB medication: findings from the Danish Registries. Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):533.
Linder M, Margulis AV, Anveden-Berglind I, Bahmanyar S, Bui CL, Atsma WJ, Appenteng K, Franks B, de Vogel S, D'Silva M, Perez-Gutthann S, Arana A. Cardiovascular risk in users of antimuscarinic drugs for overactive bladder: a cohort study in the Swedish National Registers. Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):491-2.
Linder M, Margulis AV, Anveden-Berglind I, Bahmanyar S, Bui CL, Atsma WJ, Appenteng K, Franks B, de Vogel S, D'Silva M, Perez-Gutthann S, Arana A. Cancer risk in users of antimuscarinic drugs for overactive bladder: a cohort study in the Swedish National Registers. Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):533-4.
Graham CN, McBride D, Miles L, Kneidl J, Mollon P. Estimation of indirect (work-related productivity) costs associated with moderate-to-severe plaque psoriasis in Germany. Poster presented at the 2015 ISPOR 18th Annual European Congress; November 2015. Milan, Italy.
Klimes J, Mollon P, Graham C, Rajnoch J, Dostal F, Skalicky D, Jordan P, Depta J. Cost-effectiveness analysis of secukinumab compared to ustekinumab in the treatment of moderate to severe plaque psoriasis in the Czech Republic. Poster presented at the 2015 ISPOR 18th Annual European Congress; November 2015. Milan, Italy.
D'Ausilio A, Aiello A, Daniel F, Graham C, Roccia A, Toumi M. A cost-effectiveness analysis of secukinumab 300 mg vs current therapies for the treatment of moderate to severe plaque psoriasis in Italy. Poster presented at the 2015 ISPOR 18th Annual European Congress; November 2015. Milan, Italy.
Williams V, Coles T, DeMuro C, Lewis S, Williams N, Yarr S, Barghout V, Lowes L, Alfano L, Goldberg B, Gnanasakthy A, Tseng B. Psychometric evaluation of the Sporadic Inclusion Body Myositis (sIBM) Physical Functioning Assessment (sIFA). Poster presented at the 1st Annual International Conference on Myositis; May 2015. Stockholm, Sweden.
Graham CN, Mollon P, Miles L, McBride D. A new cost-effectiveness framework for modeling psoriasis treatment. Poster presented at the 2015 ISPOR 20th Annual International Meeting; May 2015. Philadelphia, PA.
Kruse-Jarres R, Gilsenan AW, Spears J, Kaye JA. Prospective, observational study of plasma-derived factor VIII/von Willebrand factor in immune tolerance induction: the PRISM registry. Haemophilia. 2015 Mar;21(2):e122-4. doi: 10.1111/hae.12590
Wolowacz SE, Petrillo J, Doward LC, Briggs A. Measuring utility for economic models within clinical trials: can we do better? Presented at the 2014 ISPOR 19th Annual International Meeting; June 3, 2014.
Kellier N, Krohn K, Gilsenan AW, Harris DH, Andrews EB, Massica D. Forteo voluntary patient registry: 3-Year progress on a prospective osteosarcoma surveillance study. Poster presented at the American Society for Bone and Mineral Research Annual Meeting; October 6, 2013.
Wheeler SB, Kohler RE, Goyal RK, Lich KH, Lin CC, Moore A, Smith TW, Melvin CL, Reeder-Hayes K, Domino ME. Is medical home enrollment associated with receipt of guideline-concordant follow-up care among low-income breast cancer survivors? Med Care. 2013 Jun;51(6):494-502.
Gilsenan AW, Kellier N, Harris DH, Andrews EB, Masica DN. Linking a voluntary patient registry with US state cancer registries for possible signal detection. Poster presented at the 28th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 23, 2012. Barcelona, Spain. [abstract] Pharmacoepidemiol Drug Saf. 2012 Aug 27; 21(suppl 3):464. doi: 10.1002/pds.3324
Roskell N, Mendelson E, Whalley D, Knight CJ. Using a condition-specific measure of patient-reported outcomes to derive utilities in myelofibrosis. Poster presented at the 2012 ISPOR 17th Annual International Meeting; June 7, 2012. Washington, DC. [abstract] Value Health. 2012 Jun; 15(4):A224-5.
Davis KL, Wei W, Kilpatrick BS, Meyers JL, Pandya N. Use of basal insulins in elderly nursing home residents with type 2 diabetes mellitus: a retrospective chart review study. Poster presented at the Annual Scientific Meeting of the American Geriatric Society; May 2012.
Wolowacz S, Jhaveri M, Tangirala K. Cost-utility model to evaluate adjuvant chemotherapy for early breast cancer in the United States. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 28, 2009.
Knoll S, Jochum D, Talbird SE. Cost-utility analysis of pneumococcal conjugate vaccines in Germany. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 2009. Paris, France. [abstract] Value Health. 2009 Oct; 12(7):A429.
Pattanayak SK, Poulos C, Yang JC, Patil SR, Wendland KJ. Of taps and toilets: quasi-experimental protocol for evaluating community-demand-driven projects. J Water Health. 2009 Sep 1;7(3):434-51.
Harris DH, Pulliam P, Kropp N. A comparison of national cancer registries in India and the United States of America. Poster presented at the International Conference on Survey Methods in Multinational, Multiregional, and Multicultural Contexts; 2008. Berlin, Germany.
Gutierrez LP, Koltowska-Haggstrom M, Jonsson PJ, Mattsson AF, Svensson D, Westberg B, Luger A. Registries as a tool in evidence-based medicine: example of KIMS (Pfizer International Metabolic Database). Pharmacoepidemiol Drug Saf. 2008 Jan 1;17(1):90-102.
Wolowacz SE, Roskell NS, Maciver F, Kelly S. Cost-utility analysis for pegaptanib in age-related macular degeneration in the UK: the impact of demographic and disease characteristics. Poster presented at the 2006 ISPOR 9th Annual European Congress; October 31, 2006. [abstract] Value Health. 2006 Nov; 9(6):A370.
Lewis SA. A practical walkthrough of an epro design kickoff. Benefits and challenges with epro: outcomes and endpoints as we emerge from the long age of paper methods. Presented at the Drug Information Association conference workshop; 2005.
Rosamond WD, Goldstein L, Felix A, Evenson K, Moncrief C. The North Carolina collaborative stroke registry: design and first year experience. Poster presented at the International Stroke Conference; 2003.
Rosamond WD, Goldstein L, Felix A, Evenson K, Asimos A, Moncrief C. The North Carolina collaborative stroke registry: a Paul Coverdell stroke registry. Poster presented at the Tri-State Stroke Network Annual Conference; 2003.
Tuells A, Arana A, Perez-Gutthann S, García-Rodríguez LA. El Proyecto BIFAP. Inv Clin Farm. 2003;0:25-6.
Doward LC, McKenna SP, Meads DM, Ratcliffe J, Whalley D, Langley PC. Investigation into the feasibility of deriving relative and absolute utility from the recurrent genital herpes quality of life questionnaire (RGHQOL). Poster presented at the 2002 ISPOR 5th Annual European Congress; November 2002. Rotterdam, The Netherlands. [abstract] Value Health. 2002 Nov; 5(6):573-4.
Funch DP, Rothman KJ, Loughlin JE, Dreyer NA. Utility of telephone company records for epidemiologic studies of cellular telephones. Epidemiology. 1996 May 7;7(3):299-302.